Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
atrial fibrillation
glucagon‐like peptide‐1 receptor agonists
overweight
semaglutide
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
26 Jul 2024
26 Jul 2024
Historique:
received:
20
05
2024
accepted:
16
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are new anti-hyperglycaemic drugs with proven cardiovascular (CV) benefit in diabetic and non-diabetic patients at high CV risk. Despite a neutral class effect on arrhythmia risk, data on semaglutide suggest a possible drug-specific benefit in reducing atrial fibrillation (AF) occurrence. To perform a meta-analysis of randomized clinical trials (RCTs) to assess the risk of incident AF in patients treated with semaglutide compared to placebo. Ten RCTs were included in the analysis. Study population encompassed 12,651 patients (7285 in semaglutide and 5366 in placebo arms), with median follow-up of 68 months. A random effect meta-analytic model was adopted to pool relative risk (RR) of incident AF. Semaglutide reduces the risk of AF by 42% (RR .58, 95% CI .40-.85), with low heterogeneity across the studies (I Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus. This effect appears to be consistent independently of the route of administration of the drug (oral or subcutaneous), the presence of underlying diabetes and BMI.
Sections du résumé
BACKGROUND
BACKGROUND
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are new anti-hyperglycaemic drugs with proven cardiovascular (CV) benefit in diabetic and non-diabetic patients at high CV risk. Despite a neutral class effect on arrhythmia risk, data on semaglutide suggest a possible drug-specific benefit in reducing atrial fibrillation (AF) occurrence.
OBJECTIVE
OBJECTIVE
To perform a meta-analysis of randomized clinical trials (RCTs) to assess the risk of incident AF in patients treated with semaglutide compared to placebo.
METHODS AND RESULTS
RESULTS
Ten RCTs were included in the analysis. Study population encompassed 12,651 patients (7285 in semaglutide and 5366 in placebo arms), with median follow-up of 68 months. A random effect meta-analytic model was adopted to pool relative risk (RR) of incident AF. Semaglutide reduces the risk of AF by 42% (RR .58, 95% CI .40-.85), with low heterogeneity across the studies (I
CONCLUSIONS
CONCLUSIONS
Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus. This effect appears to be consistent independently of the route of administration of the drug (oral or subcutaneous), the presence of underlying diabetes and BMI.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14292Informations de copyright
© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Ussher JR, Drucker DJ. Glucagon‐like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20:463‐474.
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP‐1 receptor agonists in patients with type 2 diabetes: a systematic review and meta‐analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653‐662.
Lincoff AM, Brown‐Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221‐2232.
Wu S, Lu W, Chen Z, Dai Y, Chen K, Zhang S. Association of glucagon‐like peptide‐1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta‐analysis of randomized controlled trials. Diabetol Metab Syndr. 2022;14:195.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio‐Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European. Eur Heart J. 2021;42:373‐498.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double‐blind, phase 3a trial. Lancet. 2019;394:39‐50.
Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo‐controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515‐527.
Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841‐851.
Wang W, Chen R, Davies AL, et al. PIONEER 11: efficacy and safety of oral semaglutide versus placebo in predominantly Chinese patients with T2D treated with diet and exercise. Diabetes Res Clin Pract. 2023;197:110316.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834‐1844.
Wilding JPH, Batterham RL, Calanna S, et al. Once‐weekly Semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989‐1002.
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3 trial. Lancet. 2021;397:971‐984.
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10:193‐206.
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414‐1425.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069‐1084.
Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post‐operative, and post‐ablation atrial fibrillation: a meta‐analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1:139‐152.
Patel KHK, Reddy RK, Sau A, Sivanandarajah P, Ardissino M, Ng FS. Obesity as a risk factor for cardiac arrhythmias. BMJ Med. 2022;1:e000308.
Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017;70:2022‐2035.
Saglietto A, Gaita F, Blomstrom‐Lundqvist C, et al. AFA‐recur: an ESC EORP AFA‐LT registry machine‐learning web calculator predicting atrial fibrillation recurrence after ablation. Europace. 2023;25:92‐100.
Pathak RK, Middeldorp ME, Meredith M, et al. Long‐term effect of goal‐directed weight management in an atrial fibrillation cohort: a long‐term follow‐up study (LEGACY). J Am Coll Cardiol. 2015;65:2159‐2169.
Mulder MJ, Kemme MJB, Allaart CP. Radiofrequency ablation to achieve durable pulmonary vein isolation. Europace. 2022;24:874‐886.
Lee G, Baker E, Collins R, Merino JL, Desteghe L, Heidbuchel H. The challenge of managing multimorbid atrial fibrillation: a pan‐European European heart rhythm association (EHRA) member survey of current management practices and clinical priorities. Europace. 2022;24:2004‐2014.
Shu H, Cheng J, Li N, et al. Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance. Cardiovasc Diabetol. 2023;22:192.
Ardissino M, Patel KHK, Rayes B, Reddy RK, Mellor GJ, Ng FS. Multiple anthropometric measures and proarrhythmic 12‐lead ECG indices: a mendelian randomization study. PLoS Med. 2023;20:e1004275.
Ernault AC, Meijborg VMF, Coronel R. Modulation of cardiac arrhythmogenesis by epicardial adipose tissue: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2021;78:1730‐1745.
Ballatore A, Gatti M, Mella S, et al. Epicardial atrial fat at cardiac magnetic resonance imaging and AF recurrence after transcatheter ablation. J Cardiovasc Dev Dis. 2024;11:137.
Saglietto A, Falasconi G, Soto‐Iglesias D, et al. Assessing left atrial intramyocardial fat infiltration from computerized tomography angiography in patients with atrial fibrillation. Europace. 2023;25:euad351.
Frea S, Andreis A, Scarlatta V, et al. Subclinical left ventricular dysfunction in severe obesity and reverse cardiac remodeling after bariatric surgery. J Cardiovasc Echogr. 2020;30:22‐28.
Liu X, Zhang Z, Song Y, Xie H, Dong M. An update on brown adipose tissue and obesity intervention: function, regulation and therapeutic implications. Front Endocrinol. 2023;13:1065263.
Beiroa D, Imbernon M, Gallego R, et al. GLP‐1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63:3346‐3358.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP‐1 receptor agonists in the treatment of type 2 diabetes ‐ state‐of‐the‐art. Mol Metab. 2021;46:46.
Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:e133429.
Lee SJ, Sanchez‐Watts G, Krieger JP, et al. Loss of dorsomedial hypothalamic GLP‐1 signaling reduces BAT thermogenesis and increases adiposity. Mol Metab. 2018;11:33‐46.
Patoulias D, Popovic DS, Stoian AP, Janez A, Sahebkar A, Rizzo M. Effect of semaglutide versus other glucagon‐like peptide‐1 receptor agonists on cardio‐metabolic risk factors in patients with type 2 diabetes: a systematic review and meta‐analysis of head‐to‐head, phase 3, randomized controlled trials. J Diabetes Complications. 2023;37:108529.
Zhao M, Du W, Zhao Q, et al. Transition of metabolic phenotypes and risk of atrial fibrillation according to BMI: kailuan study. Front Cardiovasc Med. 2022;9:888062.
Corica B, Romiti GF, Proietti M, et al. Clinical outcomes in metabolically healthy and unhealthy obese and overweight patients with atrial fibrillation: findings from the GLORIA‐AF registry. Mayo Clin Proc. 2024;99:927‐939.
Poggi AL, Gaborit B, Schindler TH, Liberale L, Montecucco F, Carbone F. Epicardial fat and atrial fibrillation: the perils of atrial failure. Europace. 2022;24:1201‐1212.
Deng Y, Li L, Li Q, et al. Central obesity as a potential causal risk factor for atrial fibrillation: evidence from Mendelian randomization study. Europace. 2024;26:euae061.